iCo Therapeutics to Present at the 15th Annual BIO CEO & Investor Conference

VANCOUVER , Feb. 5, 2013 /CNW/ - iCo Therapeutics Inc. ("iCo" or "the Company") (ICO.V), today announced it will be presenting at the 15^th Annual BIO CEO & Investor Conference in New York City.  iCo Therapeutics management will deliver a company presentation to conference attendees on Tuesday, February 12 at 1:30 PM ET in the Park South Room at the Waldorf Astoria Hotel.

Mr. Rae commented that, "BIO CEO is a great platform to be in front of a mix of institutional investors, analysts, bankers and retail investors at the same time and provide an update on our clinical pipeline.  We recently announced an enrollment and safety update on our Phase 2 iDEAL study for diabetic macular edema, as that program is well on pace to provide primary endpoint data later this year."

About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or generics by employing reformulation and delivery technologies for new or expanded use indications. The company has exclusive worldwide rights to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2 clinical studies for DME. With Phase 2 clinical history, iCo-008 is targeted for the treatment of keratoconjunctivitis and wet age-related macular degeneration. In addition, iCo holds worldwide rights to an oral drug delivery platform. The first platform candidate is the Oral Amp B Delivery system, utilizing a known anti-fungal drug to treat life-threatening infectious diseases.  iCo trades on the TSX Venture Exchange under the symbol "ICO".  For more information, visit the Company website at: www.icotherapeutics.com.

No regulatory authority has approved or disapproved the content of this release.  The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.   

Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo's current beliefs as well as assumptions made by and information currently available to iCo and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo in its public securities filings; actual events may differ materially from current expectations. iCo disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: iCo Therapeutics Inc.